Extended Data Fig. 9: Evidence supporting the role of PBAF subunits in the prognosis of multiple myeloma patients.

a, Survival analysis of multiple myeloma patients (GSE57317) using probe sets for PBAF subunits other than those used in Fig. 5a (top) and using representative probe sets for Ikaros, Aiolos, and IRF4 (bottom). P-values were calculated by log rank test (two-sided). b, Survival analysis of different multiple myeloma patients (GSE2658, n=351) using representative probe sets for PBAF subunits. P-values were calculated by log rank test (two-sided). c, Hematoxylin-eosin staining of five paired samples (the first diagnosis and relapse) from multiple myeloma patients (related to Fig. 5e). The scale bars indicate 100 µm. d, Validation of antibody specificity of anti-ARID2 used for immunohistochemical analysis in Fig. 5e. Control OPM2 cells and OPM2 cells expressing shRNA #1 against ARID2 were subjected to immunofluorescence staining. The scale bars indicate 30 µm. This experiment was performed only once. e, Semi-quantitative analysis of ARID2 signals using IHC profiler. For boxplot, each center line, box limits, whiskers, and points represent median, upper and lower quartiles, the maximum or minimum value within 1.5x interquartile range from hinges, and outliers, respectively.